# IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

> **NCT04665362** · PHASE1 · UNKNOWN · sponsor: **Liang Peng** · enrollment: 10 (estimated)

## Conditions studied

- Advanced/Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib

## Key facts

- **NCT ID:** NCT04665362
- **Lead sponsor:** Liang Peng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-25
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-10-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665362, "IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04665362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*